Companies/Zymeworks Inc.

Company profile

Zymeworks Inc.

NASDAQ: ZYME · Healthcare · Biotechnology

Canadian filerHQ Middletown, BCCIK 0001937653Reports USD

#341 of 1,394 Healthcare companies by revenuetop-quartile growth

EA Score

54D

FH 62DQ 48GM 35SS 69

v0.1 · 65/100 weight · provisional

↑ market scale, balance-sheet leverage · ↓ growth stability, 3-yr revenue growth

Methodology →

Revenue TTM

$81.3M

Rev growth YoY (TTM)

-13.0%

Net income (FY)

-$81.1M

Employees

299

Market cap

$1.9B

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$106.0M$106.0M2025

Net income-$81.1M-$81.1M2025

Operating income-$92.5M-$92.5M2025

Total assets$346.5M$346.5M2025

Liabilities$78.0M$78.0M2025

Equity$268.5M$268.5M2025

Revenue trend

FY2022 – FY2025 · USD

$39.0M

FY22

$26.7M

FY22

$412.5M

FY22

$76.0M

FY23

$76.3M

FY24

$106.0M

FY25

Revenue by segment

Filed disclosures · FY2025

By product

Milestone Revenue62%

Option Exercise Fee18%

Research Support Payments And Other Service14%

Royalty6%

By geography

Not disclosed.

The read

Zymeworks Inc. booked $106.0M in FY2025 revenue, growing 39% year over year — faster than most Healthcare companies we track, at a -76.6% net margin.

Peers · Healthcare

Syndax Pharmaceuticals, Inc.52D MBX Biosciences, Inc. Common Stock——Rest Ez Inc.——ANI Pharmaceuticals, Inc.82B+

Key facts

CEOKenneth H. Galbraith

SectorHealthcare

IndustryBiotechnology

HeadquartersMiddletown, BC

ExchangeNASDAQ: ZYME

Employees299

IPO date2017-04-28

Latest filings

8-K2026-06-29 8-K2026-05-14 10-Q2026-05-07 8-K2026-05-07 8-K2026-04-01 10-K2026-03-02 8-K2026-03-02 8-K2026-03-02

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.